

ABSTRACT

The present invention generally relates a method of detecting type
5 III mutant EGF receptor (EGFRvIII) in biological samples, a method of
detecting cancers and other diseases in biological samples, and to a
method of assessing treatment and selecting therapy for cancer patients.

PATENT 4320300